News
-
-
-
-
-
-
-
-
-
PRESS RELEASE
Original-Research: Valneva SE (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research GmbH updates research on Valneva SE, maintaining Buy rating and lowering target price from €4.50 to €4.40 following Q2 results, projecting rebound in gross margin and likelihood of FDA approval for Lyme disease vaccine candidate LB6V -